Psomagen, Inc.

• Booth: 1715

Psomagen, Inc., formerly Macrogen USA, is a North American contract laboratory services provider. The company makes cutting-edge genomics, epigenomics, metagenomics, transcriptomics, and proteomics technologies accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers the highest-quality integrative multiomics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable.

 Press Releases

• Psomagen, Inc. Makes Key Tools and Technologies Accessible and Scalable Through Partnerships With 10x Genomics and Olink Proteomics (Jan 28, 2022)

  New Collaborations Will Accelerate the Impact of Multiomics on Human Health

  ROCKVILLE, Md. — January 20, 2021 — After finalizing partnerships with 10x Genomics and Olink Proteomics in 2021, Psomagen, Inc., is beginning 2022 by bringing end-to-end multiomics solutions to the drug discovery and development, diagnostics, and clinical research industries. 

  For nearly two decades, Psomagen has been providing next-generation sequencing to the life sciences industry. Its newest services — which include single-cell sequencing (SCS) and protein biomarker discovery — shift its focus to a bigger-picture approach that will deliver a greater understanding of how behavior, environment, and genes can influence disease.

  “We’re committed to bridging the gap between biomedical research and individualized healthcare,” said Ryan Kim, CEO at Psomagen. “We concentrate on building relationships with state-of-the-art solutions providers, become trusted experts in their tools and technologies, and then bring those benefits straight to our customers.” 

  Today Psomagen is a 10x Certified Service Provider (CSP) for 3’ and 5’ Single Cell Gene Expression and Single Cell Immune Profiling, and the only CSP in the United States to offer both Single Cell Multiome ATAC + Gene Expression and Single Cell ATAC. Additionally, the company offers Olink Proteomics’ Explore 1536 & 3072 Platform, Target 96 Panels, Target 48 Cytokine, and Focus 21 Custom Panels. 

  “We are delivering cutting-edge solutions in an efficient and scalable manner that lowers the barrier to entry for our customers looking to find new ways to fight disease,” said Su Hong, Ph.D., Director of Strategy Development at Psomagen. 

  Learn more about Psomagen’s US-based CLIA-certified and CAP-accredited facilities, and genomics, epigenomics, transcriptomics, and proteomics offerings at www.psomagen.com. 

  About Psomagen, Inc.

  Psomagen, Inc., formerly Macrogen USA, is a North American contract laboratory services provider. The company makes cutting-edge genomics, epigenomics, metagenomics, transcriptomics, and proteomics technologies accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multiomics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable.

• Psomagen, Inc. Partners with Swift Biosciences to Fill the Increasing Need for Genomic Surveillance of SARS-CoV-2 Variants (Jan 28, 2022)

  ROCKVILLE, MD — April 13 2021 — Psomagen, Inc., a US-based genetic sequencing and data analysis service provider, is collaborating with Swift Biosciences (now part of Integrated DNA Technologies), a pioneer in the development of research-use-only library preparation kits, to offer comprehensive SARS-CoV-2 variant determination using next-generation sequencing (NGS).

  Early in the pandemic, public health officials recognized the need to characterize the virus that causes COVID-19. But as the virus spreads, managing the volume of patient samples slated for sequencing for surveillance research has become a challenge. 

  That’s where Psomagen’s partnership with Swift comes in. 

  Psomagen currently offers two EUA-approved COVID-19 diagnostics tests including SalivaDirect and the Psoma COVID-19 RT Coronavirus Test. Adding the Swift Normalase®️ Amplicon SARS-CoV-2 Panel (SNAP) has allowed them to diversify existing screening efforts to include variant profiling. 

  “Our labs have scaled up and we are ready to help our peers trying to balance COVID-related sequencing with non-COVID projects,” said Ryan Kim, Chief Executive Officer at Psomagen. “Getting these samples processed quickly is important because the resulting information is helping to fight against the spread of the disease.”

  Swift’s SNAP SARS-CoV-2 overlapping primers may help facilitate 99.7% coverage of the SARS-CoV-2 genome. The one-tube multiplex technology facilitates identification even in cases where a mutation occurs under a primer binding site.

  “That means the data is really accurate—if there are variants from the original NCBI Reference Sequence NC_045512.2 Wuhan-Hu-1, you will see it,” said Jordan RoseFigura, Director of Manufacturing Sciences at Swift Biosciences. “That is crucial because even the slightest genetic anomaly could change the severity and transmissibility of the disease.”

• Psomagen, Inc. is partnering with Olink Proteomics, enabling unprecedented multiomics clinical studies (Jan 28, 2022)

  ROCKVILLE, Md. — November 11, 2021 — Psomagen, Inc., a North American sequencing-based contract laboratory service and data analysis provider with both CLIA-certified and CAP-accredited facilities, has partnered with Olink Proteomics, which offers an innovative DNA-coupled immunoassay that identifies and quantifies protein biomarkers in clinical samples. The partnership enables end-to-end multi-omics clinical studies, a step that will enable a whole new generation of precision therapies derived from a more robust knowledge of human biology.

  “This is the kind of partnership that can transform the pharmaceutical industry,” said Take Ogawa, Chief Commercial Officer at Psomagen. “Today, drug developers are piecemealing together information from clinical research that is disjointed and resource-draining, but that is about to change.” 

  Olink’s technology — called the Proximity Extension Assay (PEA) — uses antibodies with DNA tags that when hybridized with extremely high specificity, can measure the protein profile in patient samples using next-generation sequencing and qPCR. Psomagen’s 17-year history as genomic sequencing and data analysis service provider makes it uniquely qualified to help drug developers add proteomics to their research strategies in this capacity. 

  “Olink’s technology is a natural extension of our current service offerings,” said Su Hong, Ph.D., Director of Strategy Development at Psomagen. “The fact that we have CLIA-certified and CAP-accredited facilities will open new doors for trailblazers who are pushing the limits of the role proteins play in developing new therapeutics.”

  The improved dynamic range and exceptional readout specificity of Olink’s DNA-based assays have revolutionized multi-omics clinical research, delivering a deeper understanding of complex human biology and making new discoveries possible.

  “Our shared mission is to help research teams meet their goals more effectively and efficiently, and fundamentally speed up the impact on the health of the world. Partnering is key in making that happen, making our technology not just accessible but also scalable across the biological discovery and drug development markets,” said Carl Raimond, Chief Commercial Officer of Olink Proteomics.

  Adding Olink® Explore platform as well as the Olink® Target 96 and Target 48 panels, which will launch in early 2022, will complement Psomagen’s existing genomics, transcriptomics, and epigenetics services, and will position the company as an integrative omics solutions provider that can uniquely deliver a comprehensive view of biology and disease to clinical researchers.  

  Learn more about Psomagen’s full array of omics services at www.psomagen.com.